I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Sutton\[[@ref1]\] described halo nevi (HNs) as leukoderma acquisita centrifugum in1916. These are common benign melanocytic nevi in which an inflammatory infiltrate develops that result in surrounding zone of depigmentation, giving rise to a halo around the melanocytic nevus.\[[@ref1]\] HN affects 1% of the population with no sex predilection.\[[@ref2]\] The association between vitiligo and halo nevi is long been debated with some authors consider halo nevi as one end of the spectrum of vitiligo,\[[@ref3]\] whereas others consider them as two different entities.\[[@ref4][@ref5][@ref6]\] HN can be traditionally associated with dysplastic nevus\[[@ref7]\] and malignant melanoma.\[[@ref8]\] Either of these conditions are extremely rare in Indian subcontinent wherein benign HN is usually encountered. Hypo- or depigmented macules on body impart a lot of psychosocial disturbances in patients with pigmented skin. Various treatment modalities ranging from no intervention\[[@ref9]\] to topical tacrolimus,\[[@ref10]\] surgical excision of nevus,\[[@ref11]\] and excimer laser\[[@ref12][@ref13]\] are reported in the literature. Monochromatic excimer light (MEL) has a similar mechanism of action to the excimer laser.\[[@ref14]\] We decided to use MEL on HN.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

After obtaining ethical clearance and informed written consent, a total of 29 consecutive patients with HN were included in the study. Site and size of HN were noted and respective demographic data were collected. Patients with generalized vitiligo, those treated with phototherapy in the past 3 months and those with a history of immunosuppressive or photosensitizing agents were excluded from the study. A dermoscopic examination of nevus was carried out in all patients to rule out atypical patterns.

Treatment protocol {#sec2-1}
------------------

A xenon chloride lamp emitting noncoherent, monochromatic 308-nm light that represents the natural evolution of the excimer laser was used.

All patients were treated with xenon chloride 308-nm MEL (Exciplex; Clarteis, Valbonne--Sophia Antipolis, France) producing 100 mW/cm^2^ power density with a total optical power of 2500 mW. The spot size available with this system is 5×5cm. A suitable silicone stencil of the size of HN was used to protect the surrounding skin to prevent burns and post-inflammatory hyperpigmentation. Treatment was started with a fluence of 100 mJ/cm^2^. The fluence was increased by 100 mJ/cm^2^ per session until a slight erythema appears after 24h. If there was intense erythema lasting for more than 48h, the next session was skipped until the erythema resolves and the dose was reduced by 100 mJ/cm^2^. The same dose was continued for the next two sessions and then it was increased by 50 mJ/cm^2^. Treatment was administered twice a week on nonconsecutive days. If the patient did not show any repigmentation even after 10 sessions, it was considered as treatment failure. And if the patient developed repigmentation in the initial sessions of treatment but did not show further improvement even after 10 continuous sessions, then the patient was labeled as a partial responder and the treatment was discontinued. Clinical photographs were taken in all the patients once a month. Two independent dermatologists evaluated the results by observing the clinical photographs. All the patients were followed up for 6 months. Side effects during the treatment were also recorded. Repigmentation was graded as:

Grade 0: no repigmentationGrade 1: 1%--24% repigmentation (partial improvement)Grade 2: 25%--49% repigmentation (good improvement)Grade 3: 50%--74% repigmentation (very good improvement)Grade 4: 75%--99% repigmentation (excellent improvement)Grade 5: 100% repigmentation (outstanding improvement)

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 29 patients with 10 males and 19 females (male to female ratio of 1:1.9) completed the study. The age of onset of HN ranged from 5 to 47 years and the mean age of the patients was 23 years. Patient characteristics, the result obtained, and doses used are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Master chart showing age, sex, site, number of session, repigmentation, and complications

  **Case no.**   **Age (years**)   **Sex**   **Site**          **Number of sessions**   **Max. dose \[mJ/cm^2^\]**   **Mean dose**   **Percentage of repigmentation (%**)   **Complication**
  -------------- ----------------- --------- ----------------- ------------------------ ---------------------------- --------------- -------------------------------------- ----------------------------------------
  1              10                M         Back              7                        700                          257             100                                    \--
  2              12                F         Lower extremity   12                       1000                         625             70                                     \--
  3              42                F         Chest             32                       2200                         893             60                                     \--
  4              28                M         Neck              17                       1300                         794             100                                    Developed vitiligo in surrounding skin
  5              5                 F         Chest             10                       400                          260             100                                    \--
  6              21                M         Trunk             21                       2500                         1171            50                                     \--
  7              12                F         Face              9                        500                          294             100                                    \--
  8              19                F         Lower extremity   10                       800                          520             0                                      \--
  9              37                M         Back              17                       1000                         735             100                                    \--
  10             29                F         Neck              39                       2800                         1671            75                                     \--
  11             9                 M         Lower extremity   28                       1100                         539             90                                     Developed vitiligo in surrounding skin
  12             11                F         Neck              12                       800                          566             100                                    \--
  13             21                F         Lower extremity   30                       2200                         1313            90                                     \--
  14             22                F         Face              32                       2000                         881             60                                     \--
  15             15                F         Trunk             10                       800                          520             100                                    \--
  16             38                M         Chest             20                       1200                         835             80                                     \--
  17             29                F         Face              8                        500                          362             0                                      Intense erythema and blistering
  18             21                F         Neck              20                       900                          695             100                                    \--
  19             32                F         Chest             10                       1000                         550             100                                    \--
  20             17                M         Back              12                       800                          566             70                                     \--
  21             47                F         Trunk             11                       900                          563             100                                    \--
  22             21                F         Trunk             26                       1400                         988             100                                    \--
  23             12                F         Face              24                       1100                         841             100                                    \--
  24             43                F         Neck              5                        400                          360             70                                     \--
  25             8                 M         Upper extremity   38                       2400                         1521            100                                    \--
  26             29                F         Back              21                       1500                         919             100                                    \--
  27             20                F         Face              16                       1400                         781             90                                     \--
  28             21                M         Lower extremity   8                        600                          412             100                                    \--
  29             40                M         Neck              26                       2800                         1288            70                                     \--

F = female, M = male

The percentage of repigmentation in different age groups and gender is shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively. HN was distributed all over the body, 5 (17.2%) patients had it on the face, 6 (20.7%) on the neck, 4 (13.7%) each on the chest, trunk, and back, and 5 (17.2%) and 1 (3.4%) on the lower and upper extremities, respectively. The number of sessions to achieve satisfactory response ranged from 5 to 39 sessions, with an average number of sessions of 18.3. The frequency of repigmentation in different body sites is shown in [Table 4](#T4){ref-type="table"}. Maximum fluence ranged from 400 to 2800 mJ/cm^2^ to attain repigmentation. The average fluence used in the study ranged from 400 to 1671 mJ/cm^2^ with a mean fluence of 748 mJ/cm^2^.

###### 

Percentage of repigmentation among different age groups

  **Crosstab**                                                           
  ------------------------ ------- ------- ------- ------- -------- ---- ---
  Age (years) (Binned)     ≤10     Count   0       1       1        2    4
  \% within age (Binned)   0.0%    25.0%   25.0%   50.0%   100.0%        
  11--20                   Count   1       1       2       4        8    
  \% within age (Binned)   12.5%   12.5%   25.0%   50.0%   100.0%        
  21--30                   Count   0       2       3       5        10   
  \% within age (Binned)   0.0%    20.0%   30.0%   50.0%   100.0%        
  31--40                   Count   1       2       0       1        4    
  \% within age (Binned)   25.0%   50.0%   0.0%    25.0%   100.0%        
  41+                      Count   0       1       0       2        3    
  \% within age (Binned)   0.0%    33.3%   0.0%    66.7%   100.0%        
  Total                    Count   2       7       6       14       29   
  \% within age (Binned)   6.9%    24.1%   20.7%   48.3%   100.0%        

###### 

Percentage of repigmentation among two genders

                     **Repigmentation**                   **Total**                 
  ------------------ -------------------- ------- ------- ----------- -------- ---- ----
  Gender             Male                 Count   0       4           1        5    10
  \% within gender   0.0%                 40.0%   10.0%   50.0%       100.0%        
  Female             Count                2       3       5           9        19   
  \% within gender   10.5%                15.8%   26.3%   47.4%       100.0%        
  Total              Count                2       7       6           14       29   
  \% within gender   6.9%                 24.1%   20.7%   48.3%       100.0%        

###### 

Percentage of repigmentation among different sites

  **Crosstab**                                                                 
  ----------------------------- ------- ------- ------- -------- -------- ---- ---
  Site                          Back    Count   0       0        0        4    4
  \% within site                0.0%    0.0%    0.0%    100.0%   100.0%        
  Upper and lower extremities   Count   1       2       2        1        6    
  \% within site                16.7%   33.3%   33.3%   16.7%    100.0%        
  Chest                         Count   1       2       0        1        4    
  \% within site                25.0%   50.0%   0.0%    25.0%    100.0%        
  Neck                          Count   0       1       2        3        6    
  \% within site                0.0%    16.7%   33.3%   50.0%    100.0%        
  Trunk                         Count   0       2       1        1        4    
  \% within site                0.0%    50.0%   25.0%   25.0%    100.0%        
  Face                          Count   0       0       1        4        5    
  \% within site                0.0%    0.0%    20.0%   80.0%    100.0%        
  Total                         Count   2       7       6        14       29   
  \% within site                6.9%    24.1%   20.7%   48.3%    100.0%        

An outstanding response was noticed in 14 (48.2%) patients \[[Figures 1--4](#F1){ref-type="fig"}\], whereas 6 (20.6%) patients showed excellent improvement \[[Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}\]. Very good and partial improvement was observed in 6 (20.6%) patients and 1 (3.4%) patient, respectively \[[Figure 7](#F7){ref-type="fig"}\]. Only 2 (6.8%) patients showed no response after 10 consecutive sessions and declared the treatment as failure. Dermoscopy showed diffuse structureless area at the periphery with reticular pigment network in the center. After treatment, it showed an increased amount of melanin in the nevus area and pockets of reticular pigment network in the white area \[[Figure 8](#F8){ref-type="fig"}\]. The lesion on the face and neck responded fast, and lesions on the extremities took relatively long time to respond. But no statistically significant difference was observed between the lesion location and the outcome of the treatment by analysis of variance, which is shown in [Table 5](#T5){ref-type="table"}.

![Clinical image of halo nevus on the face showing outstanding improvement after MEL treatment](JCAS-12-17-g001){#F1}

![Clinical image of halo nevus on the face showing outstanding improvement after MEL treatment](JCAS-12-17-g002){#F2}

![Clinical image of halo nevus on the back showing outstanding improvement after MEL treatment](JCAS-12-17-g003){#F3}

![Clinical image of halo nevus on the chest showing outstanding improvement after MEL treatment](JCAS-12-17-g004){#F4}

![Clinical image of halo nevus on the thigh showing excellent improvement after MEL treatment](JCAS-12-17-g005){#F5}

![Clinical image of halo nevus on the back showing outstanding improvement after MEL treatment](JCAS-12-17-g006){#F6}

![Clinical image of halo nevus on the upper leg showing very good improvement after MEL treatment](JCAS-12-17-g007){#F7}

![(A) Dermoscopy of halo nevus showing pigment network (yellow star) in the center surrounded by diffuse structureless white areas (black stars) (left panel). (B) After treatment, faint pigment network (black arrows) is well appreciated in the white structureless area and also note the increased melanin amount in the pigment network (blue star) (right panel)](JCAS-12-17-g008){#F8}

###### 

Range of variation in the repigmentation in different parts of the body

  **Site**      **Number of sessions (mean ± SD**)   **Maximum dose \[mJ/cm^2^\]**   **Minimum dose \[mJ/cm^2^\]**   **Percentage of repigmentation (mean ± SD**)
  ------------- ------------------------------------ ------------------------------- ------------------------------- ----------------------------------------------
  Face          17.8±10.2                            1100±636.3                      631.8±280                       98.0±4.4
  Neck          19\. 8±11.7                          1500±1046.9                     895±490                         87.5±14
  Chest         18.0±10.4                            1200±748.3                      634.5±291.2                     55±41.2
  Trunk         17.0±7,78                            1400±778                        810.5±319                       77.5±22.1
  Back          14.2±6.07                            1000±355.9                      619.2±218.2                     100
  Extremities   21.0±12.5                            1350±758.2                      821.6±192.1                     68.3±35.4

SD = standard deviation

All patients tolerated the procedure well. Only one patient with HN on the chest developed intense erythema and blistering at the site, which resolved on its own. This particular lesion did not respond to treatment. Two patients developed vitiligo in the perilesional skin during the course of treatment but both of them responded to MEL with complete repigmentation. We did not contemplate perilesional hyperpigmentation as a complication rather it was considered as the normal outcome of treatment as the patients in this study were of skin type 4 and 5. However, it was minimized by using silicone stencils and interestingly, it resolved in all patients after discontinuation of MEL.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

HN is found most commonly in children. The average age of onset is 15 years. In our study, it was 23 years. There is no predilection for sex or race.\[[@ref2]\] In our study, female outnumbered male by 2:1 ratio. This can be attributed to greater awareness in the female subjects because of social stigma.

HNs can develop anywhere on the body but are seen most frequently on the trunk.\[[@ref15]\] The neck is the most common site involved in our study followed by the face and lower extremity.

The treatment of HN is controversial. There are reports for spontaneous resolution of halo nevi with the disappearance of nevus and repigmentation of halo.\[[@ref9]\] The appearance of halo represents the onset of nevus regression and disappearance of nevus leaving behind a depigmented halo. Eventually, the halo gets repigmented spontaneously.\[[@ref15][@ref16]\] Aouthmany *et al.*\[[@ref17]\] reported the average duration for complete resolution of the halo as 7.8 years. They also reported that 51% of HN showed no change after an average of 4.2 years, and 78% of HN failed to resolve during an average follow-up of 5.6 years.\[[@ref17]\] Such a long duration for spontaneous resolution is unacceptable in our patients.

There are not many reports on the treatment of HN. Hossain\[[@ref10]\] treated two cases of benign halo nevi with topical tacrolimus ointment. Wang *et al.*\[[@ref11]\] treated HN by complete excision. They also reported repigmentation of associated vitiligo following excision. Excision of HN is not always possible because of the size and location. The resulting scar may be unacceptable to many of the patients, and the frequency of achieving the regression of depigmented halo after excision is lesser and sometimes it takes place after many years.\[[@ref11]\]

Excimer lasers are sometimes called as "exciplex" lasers, which are pulsed gas lasers typically emitting ultraviolet light. The term "excimer" is used as the short form of "excited dimer." It uses noble gas and halide molecules. The 308-nm MEL particularly uses xenon as a noble gas and chloride as a halide molecule.

MEL has a similar mechanism of action as that of a laser.\[[@ref14]\] It emits monochromatic ultraviolet light of 308-nm wavelength, which unlike laser is non-collimated and noncoherent. It causes T cell apoptosis resulting in immunosuppression. It also results in DNA damage and stimulates melanocytic-stimulating hormone and melanocytic proliferation. These effects eventually bring in the repigmentation in the depigmented areas of vitiligo or HN.\[[@ref18][@ref19]\] Localized vitiligo responded well with MEL in many studies and the most effective result was observed in the lesions on the face and neck.\[[@ref11]\] Chimento *et al.*\[[@ref20]\] in a pilot study treated 10 patients of stable vitiligo with ME and concluded that 308-nm MEL is a safe and effective therapeutic option in patients with stable vitiligo in skin types 3 to 6. Nisticò *et al.*\[[@ref21]\] studied 53 patients of vitiligo and concluded that 308-nm MEL alone or in combination with 0.1% tacrolimus is effective in the treatment of vitiligo.

Mulekar *et al.*\[[@ref12]\] treated four cases of HN on the face with an excimer laser. They reported 100% repigmentation in two cases and 80% repigmentation in the remaining two cases. They also reported retention of pigment at 18 months follow-up without any changes suggestive of melanoma.\[[@ref12]\]

On the basis of this report and reports of successful treatment of vitiligo with MEL,\[[@ref22]\] we decided to treat HN with MEL. In this study, patients with lesions affecting the facial and non-facial areas were selected. All patients showed improvement ranging from outstanding to good except two patients in whom no improvement was reported even after 10 consecutive sessions. No malignant changes were noticed in this study following MEL treatment. No statistically significant variation was reported in the treatment outcome based on the location of the lesion. However, lesions located on the face and neck responded faster as compared to that on the other areas. No studies are available to compare this entity in the literature. Nevertheless, in vitiligo, MEL produces better results in the facial and neck lesions as compared to lesions affecting other areas of the body.\[[@ref23]\]

Association of melanoma with HN or development of melanoma following MEL treatment of HN is a great concern. There are reports to support the occurrence of melanoma after ablative lasers treatment.\[[@ref24]\] A large systematic review by Eggen *et al.*\[[@ref25]\] found no evidence of malignant transformation of congenital melanocytic nevus treated with lasers. In a doubtful case, dermoscopy or biopsy should be carried out to rule out melanoma. Having said this, it is also important to remember that incidence of melanoma in skin types 4, 5, and 6 is very low. A study by Weyant *et al.*\[[@ref26]\] also confirmed that HN arise from a variety of histologic types of nevi, most of which are not dysplastic. Kolm *et al.*\[[@ref27]\] examined 138 HN in 87 patients with dermoscopy and found that HN exhibits the characteristic dermoscopic feature of benign melanocytic nevi. Thus, we believe that MEL in HN is a good therapeutic option because repigmentation occurs with a rapidity, which is also cosmetically acceptable by the patients. In this study, repigmentation was satisfactory in most patients. Although no significant difference in the treatment outcome between the sites and size of HN was observed, lesions on the face and neck achieved faster repigmentation as compared to lesions present in other areas.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

HN causes apprehension in the Indian population because of the social stigma associated with depigmented or hypopigmented patches on the body. Mere observation and carrying out simple follow-ups in treatment protocol are not sufficient. Hence HN should be treated. MEL is a noninvasive procedure, which results in excellent repigmentation of HN without scarring.
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